Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$676 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-5.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
16.3
Industry P/E
--
EV/EBITDA
-3.5
Div. Yield
0 %
Debt to Equity
-0.4
Book Value
$--
EPS
$-3.1
Face value
--
Shares outstanding
128,923,295
CFO
$-339.94 Mln
EBITDA
$-373.92 Mln
Net Profit
$-375.34 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
COMPASS Pathways (CMPS)
| -16.1 | -16.1 | -16.1 | 107.5 | -16.5 | -31.2 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
COMPASS Pathways (CMPS)
| 82.5 | -56.5 | 9.0 | -63.7 | -53.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
COMPASS Pathways (CMPS)
|
5.8 | 675.6 | 0.0 | -287.9 | -- | -565.3 | -- | 16.3 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of... treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom. Address: 33 Broadwick Street, London, United Kingdom, W1F 0DQ Read more
CEO & Director
Mr. Kabir Nath M.A., M.B.A.
CEO & Director
Mr. Kabir Kumar Nath M.A., M.B.A.
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of COMPASS Pathways Plc (CMPS) is $5.79 (NASDAQ) as of 02-Apr-2026 19:47 EDT. COMPASS Pathways Plc (CMPS) has given a return of -16.46% in the last 3 years.
Since, TTM earnings of COMPASS Pathways Plc (CMPS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.24
|
-12.23
|
|
2024
|
-1.67
|
1.67
|
|
2023
|
-4.58
|
2.40
|
|
2022
|
-3.72
|
1.88
|
|
2021
|
-12.89
|
3.25
|
The 52-week high and low of COMPASS Pathways Plc (CMPS) are Rs 8.90 and Rs 2.25 as of 05-Apr-2026.
COMPASS Pathways Plc (CMPS) has a market capitalisation of $ 676 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in COMPASS Pathways Plc (CMPS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.17
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.